Journal of the American Chemical Society
Page 8 of 9
Notes
1
The author declare no competing financial interest.
This research is supported by the NSF, CHE-1362959. We thank
Bruce Noll, Bruker AXS Inc, for help with solving a difficult xray
structure of compound 6.
2
3
ACKNOWLEDGMENT
4
5
This paper is dedicated to Al Padwa, a mentor and friend, on the
occasion of his 80th birthday.
REFERENCES
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
(1) Schreiber, S. L. Science, 2000, 287, 1964.
J.; Arvanites, A. C.; Morimoto, R. I.; Ferrante, R. J.; Kirsch, D. R.;
Silverman, R. B. J. Med. Chem. 2011, 54, 2409. (d) Rajabi, M.;
Mansell, D.; Freeman, S.; Bryce, R. Eur. J. Med. Chem. 2011, 46,
1165. (e) Guan, J.; Wang, X.; Smith, K.; Ager, A.; Gettayacamin,
M.; Kyle, D. E.; Milhous, W. K.; Kozar, M. P.; Magill, A. J.; Lin,
A. J. J. Med. Chem. 2007, 50, 6226.
(13) Overall ten products were characterized by x-ray analysis.
Non-crystalline compounds were characterized by solution NMR
and their structure confirmed with the help of DU8+ NMR compu-
tations described in ref. 14.
(14) (a) Kutateladze, A. G.; Reddy, D. S. J. Org. Chem., 2017,
82, 3368 (b) Kutateladze, A. G.; Mukhina, O. A. J. Org. Chem.
2015, 80, 10838. (c) Kutateladze, A. G.; Mukhina, O. A. J. Org.
Chem., 2015, 80, 5218. (d) Kutateladze, A. G.; Mukhina, O. A. J.
Org. Chem. 2014, 79, 8397.
(15) (a) Truhlar, D. G.; Gao, J.; Alhambra, C.; Garcia-Viloca,
M.; Corchado, J.; Sanchez, M. L.; Villa, J. Acc. Chem. Res. 2002,
35, 341. (b) Basran, J.; Sutcliffe, M. J.; Scrutton, N. S. Biochemis-
try, 1999, 38, 3218. (c) Brooks, H. B.; Jones, L. H.; Davidson, V.
L. Biochemistry 1993, 32, 2725.
(16) (a) Garcia-Garibay, M. A.; Gamarnik, A.; Pang, L.; Jenks,
W. S. J. Am. Chem. Soc. 1994, 116, 12095. (b) Garcia-Garibay, M.
A.; Gamarnik, A.; Bise, R.; Pang, L.; Jenks, W. S. J. Am. Chem.
Soc. 1995, 117, 10264. (c) Johnson, B. A.; Gamarnik A.; Garcia-
Garibay, M. A. J. Phys. Chem. 1996, 100, 4697. (d) Gamarnik, A.;
Johnson, B. A.; Garcia-Garibay, M. A. J. Phys. Chem. A., 1998,
102, 5491. (e) Johnson, B. A.; Kleinman, M. H.; Turro, N. J.; Gar-
cia-Garibay, M. A. J. Org. Chem. 2002, 67, 6944.
(17) (a) Caremella, P.; Cellerino, G.; Coda, A. C.; Invernizzi, A.
G.; Grunanger, P.; Houk K. N.; Albini, F. M. J. Org. Chem. 1976,
41, 3349. (b)Wang, J.-F.; Wang, J.-F. Wei, D.-Q.; Wang, C.-F.; Ye,
Y.; Li, Y.-X., Luo, Y.; Wang, W.-W.; Liu, L.-Z.; Zhao, Y.-F. J.
Theor. Comp. Chem. 2007, 6, 861. (c) Rossbach, J.; Harms, K.;
Koert, U. Org. Lett. 2015, 17, 3122. (d) Kesornpun, C.; Aree, T.;
Mahidol, C.; Ruchirawat, S.; Kittakoop, P. Angew. Chem. Int. Ed.
2016, 55, 3997.
(2) (a) Wender, P.A.; Quiroz, R.V.; Stevens, M. C. Acc. Chem.
Res. 2015, 48, 752. (b) Wender, P.A.; Verma, V A.; Paxton,, T. J.;
Pillow, T. H. Acc. Chem. Res. 2008, 41, 40.
(3) Newhouse, T.; Baran, P. S.; Hoffmann, R. W. Chem. Soc.
Rev. 2009, 38, 3010.
(4) (a) the first general index of molecular complexity was de-
veloped by Bertz, S. H. J. Am. Chem. Soc. 1981, 103, 3599. (b)
for the most recent overview of various methods to define molecu-
lar complexity and the many roles of molecular complexity in drug
discovery see Méndez-Lucio, O.; Medina-Franco, J. L. Drug Disc.
Today 2017, 22, 120. (c) we are aware of two computational
sources available in the public domain for evaluating molecular
oped by Actelion Pharmaceuticals Ltd.
(5) Kärkäs, M. D.; Porco, J. A. Jr.; Stephenson, C. R. J. Chem.
Rev. 2016, 116, 9683.
(6) Remy. R.; Bochet, C. G. Chem. Rev. 2016, 116, 9816.
(7) Triplet state cycloadditions are also well-precedented, se-
lected examples: (a) Wagner P. J. Acc. Chem. Res. 2001, 34, 1. (b)
Griesbeck, A. G.; Stadtmüller, S. J. Am. Chem. Soc. 1990, 112,
1281 (c) Zeidan, T. A.; Kovalenko, S. V.; Manoharan, M.; Clark,
R. J.; Ghiviriga, I.; Alabugin, I. V. J. Am. Chem. Soc. 2005, 127,
4270.
(8) (a) O. A. Mukhina, N. N. B. Kumar, T. M. Arisco, R. A.
Valiulin, G. A. Metzel, A. G. Kutateladze, Angew. Chem., Int. Ed.
2011, 50, 9423. (b) N. S. Nandurkar, N. N. B. Kumar, O. A.
Mukhina, A. G. Kutateladze, ACS Comb. Sci. 2013, 15, 73. (c) N.
N. B. Kumar, O. A. Mukhina, A. G. Kutateladze, J. Am. Chem.
Soc., 2013, 135, 9608. (d) W. C. Cronk, O. A. Mukhina, A. G.
Kutateladze, J. Org. Chem., 2014, 79, 1235. (e) N. N. B. Kumar,
D. M. Kuznetsov, A. G. Kutateladze, Org. Lett., 2015, 17, 438. (f)
O. A. Mukhina, N. N. B. Kumar, T. M. Cowger, A. G. Kutateladze,
J. Org. Chem., 2014, 79, 10956. (g) W. J. Umstead, O. A. Mukhina,
A. G. Kutateladze, Eur. J. Org. Chem., 2015, 2205. (h) W. J. Um-
stead, O. A. Mukhina, A. G. Kutateladze, Aust. J. Chem. 2015, 68,
1672. (i) O. A. Mukhina, D. M. Kuznetsov, T. M. Cowger, A. G.
Kutateladze, Angew. Chem. Int. Ed., 2015, 39, 11516.
(9) Kuznetsov, D.M.; Mukhina, O.A.; Kutateladze, A.G. Angew.
Chem., 2016, 55, 6988.
(10) Mukhina, O.A.; Cronk, W.C.; Kumar, N.N.B.; Sekhar, M.;
Samanta, A.; Kutateladze, A.G. J. Phys. Chem. A., 2014, 118,
10487.
(11) (a) Wagner, P. J. J. Am. Chem. Soc. 1967, 89, 5715. (b) Dal-
ton, J. C.; Turro, N. J.; Annu. Rev. Phys. Chem. 1970, 21, 499. (c)
Wagner, P. J. Acc. Chem. Res. 1971, 4, 1681. (d) Barltrop, J. A.;
Carless, H. A. J. J. Am. Chem. Soc. 1971, 93, 4794. (e) Barltrop, J.
A.; Carless, H. A. J. J. Am. Chem. Soc. 1972, 94, 8761. (f) Wagner,
P. J.; Kochevar, I. J. Am. Chem. Soc. 1969, 90, 2232.
(12) large number of biologically active compounds possessing
the imidazolidine-4,5-dione moiety have been reported (a) Arafa,
R. K.; Nour, M. S.; El-Sayed, N. A. Eur. J. Med. Chem. 2013, 69,
498. (b) Abou-Seri, S. M.; Farag, N. A.; Hassan, G. S. Chem.
Pharm. Bull. 2011, 59, 1124. (c) Xia, G.; Benmohamed, R.; Kim,
(18) Vatsadze, S. Z.; Loginova, Y. D.; Gomes, G. d. P.; Ala-
bugin I. V. Chem. Eur. J. 2017, 23, 3225.
8
ACS Paragon Plus Environment